Oxford spinout Alethio raises $90M Series A for chronic blood cancer trials, co-led by Sofinnova Partners and RA Capital.
Amount Raised
$90 Million
Round Type
Series A
OxfordBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
Alethio, a biotech spinout from Oxford's MRC Weatherall Institute, raised $90M in Series A funding to advance clinical trials for myeloproliferative neoplasms (MPNs), a group of chronic blood cancers. The round was co-led by Sofinnova Partners and RA Capital, with participation from founding investor Oxford Science Enterprises, Cancer Research Horizons, and the University of Oxford. Founded in late 2021, Alethio was created by merging two Oxford research groups studying malignant stem cells and platelet-producing cells. The company is developing a therapeutic approach targeting G6B, a protein selectively expressed on disease-driving cells, to treat MPNs including essential thrombocythemia.
Quick answer
Alethio raised $90 Million in a Series A round, dated November 5, 2026. Investors: University Of Oxford, Cancer Research Horizons, Oxford Science Enterprises, RA Capital and Sofinnova Partners. Alethio is based in Oxford, England, United Kingdom.
- How much did Alethio raise?
- Alethio raised $90 Million in a Series A round on November 5, 2026.
- Who invested in Alethio?
- University Of Oxford, Cancer Research Horizons, Oxford Science Enterprises, RA Capital and Sofinnova Partners are named as investors in this round.
- What does Alethio do?
- Alethio is an Oxford spinout founded in 2021 that develops targeted therapies for chronic blood cancers, specifically myeloproliferative neoplasms (MPNs).
- Where is Alethio based and how big is it?
- Alethio is based in Oxford, England, United Kingdom. Fundz records about 2 employees.
- Who are the decision-makers at Alethio?
- Fundz holds 3 contacts at Alethio, including the Head of Bioinformatics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Alethio that raised within 45 days of this round, from Fundz verified event records.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- StimCardio raised $30M (Series A) on October 29, 2026.
- Tivic raised $85M (Series B) on October 27, 2026.
- Tivic raised $8.4M (Series B) on October 8, 2026.
- Rouge Therapeutics raised $58M (Series A) on October 6, 2026.
- Omnio raised $3.3M (Seed) on October 2, 2026.
Who to call at Alethio, and when
A new round usually means Alethio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alethio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alethio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alethio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alethio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAlethio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.